Motor cortical function determines prognosis in sporadic ALS

Objective: To study the relationship between cortical function and survival in amyotrophic lateral sclerosis (ALS). Methods: A total of 216 referrals were screened, and participants with familial ALS or an inexcitable cortex were excluded. Clinical measures and phenotyping from 169 patients with sporadic ALS were combined with an assessment of cortical function using threshold tracking transcranial magnetic stimulation with indices including short interval intracortical inhibition (SICI). Peripheral nerve studies were collected, incorporating compound muscle action potential amplitude. Clinical prognostic factors were recorded longitudinally, including ALS Functional Rating Scale–Revised (ALSFRS-R). Results: Compared to 109 healthy controls, 169 patients had reduced SICI (p < 0.0001). In survival analysis, 105 patients progressed to death with an estimated median survival time of 37 months. In patients with less than 2 years disease duration (n = 140), those with bulbar onset (p = 0.017), rapid vital capacity (VC) decline (p < 0.0001), rapid ALSFRS-R decline (p < 0.0001), and reduced averaged SICI (p = 0.047) had a poorer prognosis. Multivariate analysis identified rapid VC decline (p < 0.0001), rapid ALSFRS-R decline (p = 0.0060), and reduced averaged SICI (p = 0.011) as factors independently associated with a shorter survival. Conclusions: Cortical dysfunction appears to be a prognostic marker in patients with ALS within 2 years of disease onset, such that patients with reduced averaged SICI, indicative of intracortical hyperexcitability, demonstrated a worse prognosis.

[1]  K. Byth,et al.  Rate of disease progression: a prognostic biomarker in ALS , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[2]  Matthew C Kiernan,et al.  Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for diagnosis of amyotrophic lateral sclerosis: a prospective study , 2015, The Lancet Neurology.

[3]  J. Rothstein,et al.  Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies , 2014, Trends in Neurosciences.

[4]  O. Hardiman,et al.  Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial , 2013, The Lancet Neurology.

[5]  E. Beghi,et al.  Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS , 2013, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.

[6]  M. Kiernan,et al.  Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. , 2013, Brain : a journal of neurology.

[7]  M. Kiernan,et al.  The Puzzling Case of Hyperexcitability in Amyotrophic Lateral Sclerosis , 2013, Journal of clinical neurology.

[8]  S. Kuwabara,et al.  Split hand syndrome in amyotrophic lateral sclerosis: different excitability changes in the thenar and hypothenar motor axons , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[9]  Mark Hallett,et al.  Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[10]  Yasunori Sato,et al.  Motor axonal excitability properties are strong predictors for survival in amyotrophic lateral sclerosis , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[11]  L. Martin,et al.  Inhibitory Synaptic Regulation of Motoneurons: A New Target of Disease Mechanisms in Amyotrophic Lateral Sclerosis , 2012, Molecular Neurobiology.

[12]  Yasunori Sato,et al.  Markedly reduced axonal potassium channel expression in human sporadic amyotrophic lateral sclerosis: An immunohistochemical study , 2011, Experimental Neurology.

[13]  C. Yiannikas,et al.  Cortical excitability distinguishes ALS from mimic disorders , 2011, Clinical Neurophysiology.

[14]  O. Hardiman,et al.  Amyotrophic lateral sclerosis , 2011, The Lancet.

[15]  S. Aiso,et al.  Aberrant Control of Motoneuronal Excitability in Amyotrophic Lateral Sclerosis: Excitatory Glutamate / D‐Serine vs. Inhibitory Glycine/γ‐Aminobutanoic Acid (GABA) , 2010, Chemistry & biodiversity.

[16]  E. Beghi,et al.  Prognostic factors in ALS: A critical review , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[17]  B. Mohammadi,et al.  ALSFRS-R score and its ratio: A useful predictor for ALS-progression , 2008, Journal of the Neurological Sciences.

[18]  M. Kiernan,et al.  Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. , 2006, Brain : a journal of neurology.

[19]  Matthew C. Kiernan,et al.  Axonal excitability properties in amyotrophic lateral sclerosis , 2006, Clinical Neurophysiology.

[20]  Matthew C Kiernan,et al.  Assessment of cortical excitability using threshold tracking techniques , 2006, Muscle & nerve.

[21]  S. Petri,et al.  Distribution of GABAA Receptor mRNA in the Motor Cortex of ALS Patients , 2003, Journal of neuropathology and experimental neurology.

[22]  Stefano Tamburin,et al.  Changes in motor cortex inhibition over time in patients with amyotrophic lateral sclerosis , 2002, Journal of Neurology.

[23]  P N Leigh,et al.  Extramotor involvement in ALS: PET studies with the GABA(A) ligand [(11)C]flumazenil. , 2000, Brain : a journal of neurology.

[24]  J. Rothwell,et al.  Direct demonstration of the effect of lorazepam on the excitability of the human motor cortex , 2000, Clinical Neurophysiology.

[25]  M. Swash,et al.  El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[26]  J. Cedarbaum,et al.  The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function , 1999, Journal of the Neurological Sciences.

[27]  D. Burke,et al.  Strength–duration properties and their voltage dependence at different sites along the median nerve , 1999, Clinical Neurophysiology.

[28]  C. Armon,et al.  Linear estimates of rates of disease progression as predictors of survival in patients with ALS entering clinical trials 1 Presented in part at the 8th International Symposium on ALS/MND held in Glasgow, Scotland, November 3–5th, 1997. 1 , 1998, Journal of the Neurological Sciences.

[29]  K. Sakai,et al.  Paired‐pulse magnetic stimulation of the human motor cortex: differences among I waves , 1998, The Journal of physiology.

[30]  D. Burke,et al.  Strength-duration properties of sensory and motor axons in amyotrophic lateral sclerosis. , 1998, Brain : a journal of neurology.

[31]  S H Appel,et al.  Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. , 1995, Brain : a journal of neurology.

[32]  C. Marsden,et al.  Corticocortical inhibition in human motor cortex. , 1993, The Journal of physiology.

[33]  F. Norris,et al.  Onset, natural history and outcome in idiopathic adult motor neuron disease , 1993, Journal of the Neurological Sciences.

[34]  J. Garthwaite,et al.  Excitatory amino acid neurotoxicity and neurodegenerative disease. , 1990, Trends in pharmacological sciences.

[35]  N. Murray,et al.  Electrical stimulation over the human vertebral column: which neural elements are excited? , 1986, Electroencephalography and clinical neurophysiology.

[36]  V. Amassian,et al.  Single and multiple-unit analysis of cortical stage of pyramidal tract activation. , 1954, Journal of neurophysiology.

[37]  A. Ludolph,et al.  Amyotrophic lateral sclerosis. , 2012, Current opinion in neurology.

[38]  Ann C. McKee,et al.  Patterns of neuronal degeneration in the motor cortex of amyotrophic lateral sclerosis patients , 2004, Acta Neuropathologica.

[39]  E. Kahana,et al.  Amyotrophic lateral sclerosis. A study of its presentation and prognosis , 2004, Journal of Neurology.